Net income
-20.5 million USD
2025-07-01 – 2026-06-30
Fundies. English
Actuate Therapeutics, Inc.
EDGAR17 filing records in this dataset, filed from 2024-05-24 to 2026-10-30. Reported financial figures are available; chart coverage varies by period.
- Cash and cash equivalents
- 4.43 million USD Source
Exact value
4425841 USD
- Long-term debt including current maturities
- Not available
- Shares outstanding
- 24 million shares Source
Exact value
24013577 shares
Reported share-count change
17.31% · 3.54 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Operating cash flow
-19.8 million USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
- Operating cash flow: -15470210 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -8792501 USD · 2025-01-01 – 2025-06-30 Source
- Operating cash flow: -19206253 USD · 2025-01-01 – 2025-12-31 Source
- Operating cash flow: -15470210 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -5017327 USD · 2026-01-01 – 2026-03-31 Source
- Operating cash flow: -9422450 USD · 2026-01-01 – 2026-06-30 Source
- Operating cash flow: -5017327 USD · 2026-01-01 – 2026-03-31 Source
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-10-30.
Financial data available through: 2025-12-31.
Coverage by financial measure
- revenue: No compatible figures in this window
- Operating income: 3 of 11 periods available· newest 2025-12-31
- Net income: 3 of 11 periods available· newest 2025-12-31
- Operating cash flow: 3 of 11 periods available· newest 2025-12-31
- capital expenditure: No compatible figures in this window
- Total assets: 3 of 11 periods available· newest 2025-12-31
- Total liabilities: 3 of 11 periods available· newest 2025-12-31
- Current assets: 3 of 11 periods available· newest 2025-12-31
- Current liabilities: 3 of 11 periods available· newest 2025-12-31
- Cash and cash equivalents: 2 of 11 periods available· newest 2025-12-31
- long term debt: No compatible figures in this window
- Shares outstanding: 3 of 11 periods available· newest 2025-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Net income
+USD 5.06 millionPrior period
−USD 27.29 million
–
Current period
−USD 22.23 million
–
Exact inputs and evidence
-22227852 − -27285328 = 5057476 USD
-27285328 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-22227852 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 2.64 millionPrior period
−USD 21.84 million
–
Current period
−USD 19.21 million
–
Exact inputs and evidence
-19206253 − -21842648 = 2636395 USD
-21842648 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-19206253 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue, Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
Revenue is not reported for this company, so its costs cannot be shown as a share of it.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Not enough comparable data to show this history.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|
Operating cash flow
Cash generated by the company’s normal business operations.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Current assets to current liabilities
Current assets divided by current liabilities.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2023 2023-01-01 – 2023-12-31 | −USD 24.74 million Exact valueExact value: -24744620 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 21.63 million Exact valueExact value: -21625167 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2024 2024-01-01 – 2024-12-31 | −USD 27.29 million Exact valueExact value: -27285328 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 21.84 million Exact valueExact value: -21842648 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2025 2025-01-01 – 2025-12-31 | −USD 22.23 million Exact valueExact value: -22227852 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 19.21 million Exact valueExact value: -19206253 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
17 filings · 533 latest values · 533 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001652935, 1652935, ACTU, edgar:1652935
Also known as ACTUATE THERAPEUTICS, INC., Actuate Therapeutics, Inc.